GLAUKOS Corp
For the period ended Sep 30, 2026. Filed Oct 28, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Oct 28, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 1. Legal Proceedings
On September 17, 2025, the Company filed a complaint against SpyGlass Pharma, Inc. (SpyGlass) and its Vice President of Clinical Research, Long Doan, in the United States District Court for the Central District of California (Case No. 8:25-cv-02105), alleging that former Glaukos senior clinical leader Mr. Doan and competitor SpyGlass engaged in the mass misappropriation and unauthorized use of the Company’s confidential information and trade secrets that Mr. Doan surreptitiously uploaded to his personal Google Drive after accepting SpyGlass's offer of employment. On December 11, 2025, after finding that the Company was likely to prevail on the merits of the case and is at risk of irreparable harm, the Court entered an injunction against both SpyGlass and Mr. Doan and in favor of the Company. In March 2026, the Company filed its First Amended Complaint asserting claims against SpyGlass and Mr. Doan, including claims under the Defend Trade Secrets Act. SpyGlass and Mr. Doan have asserted various counterclaims against the Company arising from the parties’ dispute, which the Company disputes. Trial is currently scheduled for January 26, 2027.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.